Compare CNXN & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | CSTL |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1998 | 2019 |
| Metric | CNXN | CSTL |
|---|---|---|
| Price | $58.16 | $39.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 63.5K | ★ 371.3K |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $2,878,704,000.00 | $343,530,000.00 |
| Revenue This Year | $5.74 | $2.55 |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | $17.87 | ★ N/A |
| Revenue Growth | 3.19 | ★ 10.15 |
| 52 Week Low | $54.97 | $14.59 |
| 52 Week High | $74.84 | $44.28 |
| Indicator | CNXN | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 46.13 |
| Support Level | $56.20 | $39.74 |
| Resistance Level | $58.44 | $44.28 |
| Average True Range (ATR) | 1.32 | 1.76 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 61.78 | 12.49 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.